… dabigatran etexilate, thereby helping to maintain an acid microenvironment. Even then, the
… bioavailability of dabigatran etexilate is only about 6.5%. The dabigatran etexilate prodrug …

… stroke prevention in NVAF and presents a cost-effectiveness … In 2010, dabigatran etexilate
became the first novel oral an… the FDA for preventing stroke and systemic embolism in patients …

… inhibitor dabigatran etexilate and the … ], dabigatran was estimated to be cost-effective
compared to warfarin in patients with atrial fibrillation at high risk of stroke, their cost-effectiveness in …

… utilization actually underrates the true cost effectiveness of NOACs, including the … cost-effectiveness
ratio estimates. Finally, the best and most cost-effective strategy of stroke prevention …

… This analysis from RELY assessed the risks of death, stroke or systemic emboli, and
bleeding according to mean achieved SBP and DBP in atrial fibrillation on oral anticoagulation. …

… Using Cox proportional hazards regression, we found that for stroke or systemic embolism,
… ), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 95…

… for the prevention of stroke or systemic embolism, Citation17 … for the prevention of ischemic
stroke or systemic embolism (… with a higher number of disabling strokes (82 vs 57 patients), …

… of evidence from individual cost-effectiveness studies. Crespo … Therefore, we conducted a
systematic review and meta-… the cost-effectiveness of using DOACs for the prevention of VTE in …

… cost-effectiveness of 30-day ECG monitoring (using an external auto-triggered event loop
recorder) after a cryptogenic stroke or … objectives were to assess the cost-effectiveness of 7-day …

… events, pulmonary embolism, systemic embolism, deep venous thromboembolism, transient
… Daily doses of dabigatran etexilate were 110 or 150 mg, rivaroxaban 15 or 20 mg, and …